Neuromod Devices Extends Global Lenire Push With New Conference Activity and Canadian Rollout

Neuromod Devices Ltd – Weekly Recap

Neuromod Devices Ltd is a medical device company focused on Lenire, a bimodal neuromodulation therapy for tinnitus. This weekly recap highlights the company’s recent commercial and clinical engagement activities across North America, Europe, and Australia, reflecting its expanding global footprint in tinnitus care.

During the week, Neuromod intensified its global push with a strong presence at key audiology conferences in the U.S. and Australia. At the American Academy of Audiology 2026 meeting in San Antonio, the company sponsored sessions on future tinnitus treatment models, showcasing data that Lenire delivered clinically significant relief in 82% of patients.

Company representatives and clinical partners detailed patient selection, clinical workflows, and real-world outcomes to position Lenire as part of mainstream audiology and ENT practice, rather than a niche add-on. In parallel, Neuromod promoted Lenire at the ACAud 2026 event in Gold Coast, Australia, where it highlighted national tinnitus prevalence data to underscore market need.

Communications in Australia described Lenire as a home-based, non-invasive solution supported by three large-scale clinical trials and real-world evidence. This evidence-led messaging appears aimed at building clinician confidence and supporting broader adoption through established audiology channels.

Neuromod also advanced its European profile at the CEORL-HNS 2026 conference in Gothenburg, Sweden, engaging with ENT and audiology specialists alongside providers such as HØR and Audioteket Sverige AB. Discussions focused on real-world clinical outcomes for tinnitus patients using Lenire, reinforcing the therapy’s practical effectiveness beyond formal trials.

By emphasizing real-world results and positioning Lenire as a “ground-breaking” tinnitus treatment, the company is seeking to differentiate its technology within the broader hearing-health market. Strengthened clinician advocacy and accumulating real-world evidence may support future reimbursement discussions and potential partnerships with healthcare systems.

Commercially, Neuromod continued expanding Lenire’s availability across Canada, where the device is now offered in 21 hearing care clinics across five provinces. Media coverage of the Canadian launch, supported by national health survey data showing high tinnitus prevalence, highlights a sizable addressable market for the therapy.

Comments from Hearing Solutions’ leadership point to rising tinnitus-related clinic visits and a need for additional treatment options, framing Lenire as a differentiated tool within non-pharmaceutical tinnitus management. Increased clinic coverage, combined with national media exposure, may enhance brand visibility and facilitate further partner-led expansion in North America.

Overall, the week underscored Neuromod Devices’ execution focus on clinician education, conference visibility, and international market rollout for Lenire. These coordinated initiatives strengthen the company’s positioning in neuromodulation-based tinnitus therapy and could support improved commercial traction over time.